Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.37
ABT's Cash-to-Debt is ranked lower than
81% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. ABT: 0.37 )
Ranked among companies with meaningful Cash-to-Debt only.
ABT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: N/A
Current: 0.37
Equity-to-Asset 0.44
ABT's Equity-to-Asset is ranked lower than
75% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABT: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
ABT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.47 Max: 0.59
Current: 0.44
0.37
0.59
Interest Coverage 4.11
ABT's Interest Coverage is ranked lower than
86% of the 225 Companies
in the Global Medical Devices industry.

( Industry Median: 77.23 vs. ABT: 4.11 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.11  Med: 10.89 Max: 17.59
Current: 4.11
4.11
17.59
Piotroski F-Score: 5
Altman Z-Score: 2.46
Beneish M-Score: -2.36
WACC vs ROIC
9.99%
10.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 11.03
ABT's Operating Margin % is ranked higher than
72% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. ABT: 11.03 )
Ranked among companies with meaningful Operating Margin % only.
ABT' s Operating Margin % Range Over the Past 10 Years
Min: 7.14  Med: 14.66 Max: 20.27
Current: 11.03
7.14
20.27
Net Margin % 6.74
ABT's Net Margin % is ranked higher than
68% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ABT: 6.74 )
Ranked among companies with meaningful Net Margin % only.
ABT' s Net Margin % Range Over the Past 10 Years
Min: 6.71  Med: 15.23 Max: 31.3
Current: 6.74
6.71
31.3
ROE % 6.59
ABT's ROE % is ranked higher than
61% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. ABT: 6.59 )
Ranked among companies with meaningful ROE % only.
ABT' s ROE % Range Over the Past 10 Years
Min: 6.59  Med: 20.51 Max: 28.49
Current: 6.59
6.59
28.49
ROA % 3.10
ABT's ROA % is ranked higher than
61% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.13 vs. ABT: 3.10 )
Ranked among companies with meaningful ROA % only.
ABT' s ROA % Range Over the Past 10 Years
Min: 2.98  Med: 8.77 Max: 12.12
Current: 3.1
2.98
12.12
ROC (Joel Greenblatt) % 30.38
ABT's ROC (Joel Greenblatt) % is ranked higher than
75% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. ABT: 30.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.81  Med: 33.56 Max: 65.75
Current: 30.38
0.81
65.75
3-Year Revenue Growth Rate 4.00
ABT's 3-Year Revenue Growth Rate is ranked lower than
54% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ABT: 4.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.9  Med: 9.7 Max: 15.2
Current: 4
-17.9
15.2
3-Year EBITDA Growth Rate -4.60
ABT's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. ABT: -4.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 9.7 Max: 31.6
Current: -4.6
-34
31.6
3-Year EPS without NRI Growth Rate -17.40
ABT's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ABT: -17.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.6  Med: 11.9 Max: 125.5
Current: -17.4
-65.6
125.5
GuruFocus has detected 5 Warning Signs with Abbott Laboratories $ABT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABT's 30-Y Financials

Financials (Next Earnings Date: 2017-07-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:SYK, NYSE:MDT, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:STJ, NYSE:SNN, NAS:ALGN, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, OTCPK:CNVVY, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, NAS:MASI, OTCPK:GGNDF, NAS:IART, NAS:NUVA » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, 0Q15.UK,
Headquarter Location:USA
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the United States.

Guru Investment Theses on Abbott Laboratories

John Rogers Comments on Abbott Laboratories - Aug 18, 2016

In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering.

From John Rogers (Trades, Portfolio)' second quarter 2016 market commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Abbott Laboratories

Abbott Hosts Conference Call for Second-Quarter Earnings
Abbott Labs Declares Quarterly Dividend Global health care company will pay its shareholders 26.5 cents per share
Abbott Laboratories (NYSE:ABT) announced a regular quarterly dividend of 26.5 cents per share June 9. Read more...
Abbott Declares 374th Consecutive Quarterly Dividend
Abbott Labs Issues Recall for HeartMate II LVAS Controller Shares of the health care company were down yesterday
After recalling its Thoratec HeartMake II LVAS controller on May 24, Abbott Laboratories (NYSE:ABT) shares declined 15 cents or 0.34%, closing at $43.53 per share.  Read more...
Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
Abbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes
AbbVie Reports Humira Sales Growth in 1st Quarter The company beat earnings, revenue expectations
AbbVie Inc. (NYSE:ABBV) released its first-quarter 2017 financial figures on April 25. Read more...
Abbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery
Abbott Laboratories Releases 1st-Quarter Numbers The Medical Devices segment drove revenue
Abbott Laboratories (NYSE:ABT) released its first-quarter results April 19. Read more...

Ratios

vs
industry
vs
history
PE Ratio 51.32
ABT's PE Ratio is ranked lower than
69% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 31.49 vs. ABT: 51.32 )
Ranked among companies with meaningful PE Ratio only.
ABT' s PE Ratio Range Over the Past 10 Years
Min: 5.78  Med: 11.28 Max: 51.32
Current: 51.32
5.78
51.32
Forward PE Ratio 20.12
ABT's Forward PE Ratio is ranked higher than
77% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ABT: 20.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 55.36
ABT's PE Ratio without NRI is ranked lower than
70% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 31.49 vs. ABT: 55.36 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.93  Med: 23.27 Max: 250.57
Current: 55.36
5.93
250.57
Price-to-Owner-Earnings 43.07
ABT's Price-to-Owner-Earnings is ranked lower than
56% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 37.06 vs. ABT: 43.07 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.53  Med: 12.4 Max: 2148.5
Current: 43.07
4.53
2148.5
PB Ratio 2.71
ABT's PB Ratio is ranked higher than
55% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. ABT: 2.71 )
Ranked among companies with meaningful PB Ratio only.
ABT' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.31 Max: 3.34
Current: 2.71
1.39
3.34
PS Ratio 3.41
ABT's PS Ratio is ranked lower than
51% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. ABT: 3.41 )
Ranked among companies with meaningful PS Ratio only.
ABT' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.92 Max: 6.24
Current: 3.41
0.96
6.24
Price-to-Free-Cash-Flow 27.27
ABT's Price-to-Free-Cash-Flow is ranked higher than
58% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 32.05 vs. ABT: 27.27 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.39  Med: 9.95 Max: 40.05
Current: 27.27
4.39
40.05
Price-to-Operating-Cash-Flow 19.27
ABT's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 20.42 vs. ABT: 19.27 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.82  Med: 7.3 Max: 23.85
Current: 19.27
3.82
23.85
EV-to-EBIT 36.71
ABT's EV-to-EBIT is ranked lower than
69% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 24.65 vs. ABT: 36.71 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 17.35 Max: 5424.4
Current: 36.71
-214.2
5424.4
EV-to-EBITDA 22.27
ABT's EV-to-EBITDA is ranked lower than
59% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 18.57 vs. ABT: 22.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 12.35 Max: 28.4
Current: 22.27
4.3
28.4
PEG Ratio 79.14
ABT's PEG Ratio is ranked lower than
96% of the 85 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABT: 79.14 )
Ranked among companies with meaningful PEG Ratio only.
ABT' s PEG Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.28 Max: 140.36
Current: 79.14
0.44
140.36
Shiller PE Ratio 17.61
ABT's Shiller PE Ratio is ranked higher than
95% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 47.60 vs. ABT: 17.61 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.03  Med: 12.82 Max: 18.1
Current: 17.61
9.03
18.1
Current Ratio 2.91
ABT's Current Ratio is ranked higher than
55% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. ABT: 2.91 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.33 Max: 4.02
Current: 2.91
0.75
4.02
Quick Ratio 2.31
ABT's Quick Ratio is ranked higher than
57% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ABT: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.99 Max: 3.65
Current: 2.31
0.55
3.65
Days Inventory 107.65
ABT's Days Inventory is ranked higher than
61% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. ABT: 107.65 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 80.31  Med: 103.72 Max: 145.14
Current: 107.65
80.31
145.14
Days Sales Outstanding 73.81
ABT's Days Sales Outstanding is ranked lower than
55% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 68.69 vs. ABT: 73.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.85  Med: 71.85 Max: 145.87
Current: 73.81
56.85
145.87
Days Payable 54.45
ABT's Days Payable is ranked lower than
51% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. ABT: 54.45 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 41.44 Max: 73.71
Current: 54.45
35.38
73.71

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.13
ABT's Dividend Yield % is ranked higher than
81% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. ABT: 2.13 )
Ranked among companies with meaningful Dividend Yield % only.
ABT' s Dividend Yield % Range Over the Past 10 Years
Min: 1.41  Med: 4.87 Max: 7.9
Current: 2.13
1.41
7.9
Dividend Payout Ratio 1.17
ABT's Dividend Payout Ratio is ranked higher than
59% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 0.36 vs. ABT: 1.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.57 Max: 13.4
Current: 1.17
0.42
13.4
3-Year Dividend Growth Rate 22.90
ABT's 3-Year Dividend Growth Rate is ranked higher than
80% of the 79 Companies
in the Global Medical Devices industry.

( Industry Median: 10.20 vs. ABT: 22.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -31.2  Med: 11.5 Max: 22.9
Current: 22.9
-31.2
22.9
Forward Dividend Yield % 2.15
ABT's Forward Dividend Yield % is ranked higher than
81% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ABT: 2.15 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.09
ABT's 5-Year Yield-on-Cost % is ranked lower than
61% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ABT: 1.09 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 2.48 Max: 4.03
Current: 1.09
0.72
4.03
3-Year Average Share Buyback Ratio 1.60
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 230 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. ABT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.5 Max: 2.2
Current: 1.6
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.41
ABT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. ABT: 1.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.86 Max: 1.81
Current: 1.41
0.36
1.81
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.18
ABT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
86% of the 28 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ABT: 5.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.78
ABT's Price-to-Median-PS-Value is ranked lower than
83% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. ABT: 1.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.85 Max: 3.11
Current: 1.78
0.5
3.11
Price-to-Peter-Lynch-Fair-Value 4.78
ABT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
82% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ABT: 4.78 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.01 Max: 6.45
Current: 4.78
0.33
6.45
Earnings Yield (Greenblatt) % 2.72
ABT's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. ABT: 2.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1  Med: 5.05 Max: 18.5
Current: 2.72
-1
18.5
Forward Rate of Return (Yacktman) % 15.69
ABT's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 8.64 vs. ABT: 15.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.6  Med: 13.25 Max: 31.8
Current: 15.69
-18.6
31.8

More Statistics

Revenue (TTM) (Mil) $22,303.00
EPS (TTM) $ 0.96
Beta1.54
Short Percentage of Float0.99%
52-Week Range $36.76 - 49.59
Shares Outstanding (Mil)1,735.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 26,361 27,505 29,239
EPS ($) 2.45 2.71 3.06
EPS without NRI ($) 2.45 2.71 3.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.26%
Dividends per Share ($) 1.10 1.16 1.24
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Daniel Eichhorn Named President and COO of PSEG Long Island Jun 23 2017 
Welltower Announces Date of Second Quarter 2017 Earnings Release, Conference Call and Webcast Jun 23 2017 
Ralph Larossa Elected President And COO Of PSEG Power Jun 23 2017 
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and Opi Jun 23 2017 
Navios Maritime Partners L.P. Announces Appointment of Mrs. Orthodoxia Zisimatou to the Board of Dir Jun 23 2017 
Sky Solar Announces Change of Official Domain Name Jun 23 2017 
Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes Jun 23 2017 
Semtech’s LoRa Technology Used by NNNCo to Develop Rural IoT Network for Australia’s Farme Jun 23 2017 
Lifetime Brands, Inc. Announces Results of 2017 Annual Meeting Jun 23 2017 
Tropicana Entertainment And Icahn Enterprises L.P. Announce Commencement Of Modified Dutch Auction T Jun 23 2017 

More From Other Websites
Abbott Hosts Conference Call for Second-Quarter Earnings Jun 21 2017
How to Uncover Institutional Buying Jun 20 2017
Abbott Laboratories :ABT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Jun 19 2017
How Stryker’s Margins Are Driven by Its CTG Program Jun 19 2017
2 Solid Medical Device Stocks to Scoop Up Right Away Jun 16 2017
ETFs with exposure to Abbott Laboratories : June 15, 2017 Jun 15 2017
The Zacks Analyst Blog Highlights: United Technologies, Abbott, Delta Air, Equity Residential and... Jun 15 2017
Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak Jun 15 2017
Alere says feds won’t take action in billing probe Jun 15 2017
Top Stock Reports for United Technologies, Abbott, Delta Air & Others Jun 14 2017
Abbott Laboratories Saw a Recent Breakout Jun 12 2017
AbbVie must pay $15 mln in Depakote birth-defect trial: jury Jun 09 2017
Abbott Labs Declares Quarterly Dividend Jun 09 2017
FDA Approval Boosts Baxter’s Generic Injectable Business Jun 09 2017
AbbVie Ordered by Jury to Pay $15 Million to Depakote Victim Jun 09 2017
Abbott Declares 374th Consecutive Quarterly Dividend Jun 09 2017
Birmingham health exec enters governor's race Jun 07 2017
Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms Jun 06 2017
Abbott Laboratories at 52-Week High on Product Line, Buyouts Jun 05 2017
3 Best Dividend Stocks in the Medical Device Industry Jun 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}